The determinants of tumour immunogenicity

Thomas Blankenstein, Pierre G. Coulie, Eli Gilboa, Elizabeth M. Jaffee

Research output: Contribution to journalArticle

152 Citations (Scopus)

Abstract

Many standard and targeted therapies, as well as radiotherapy, have been shown to induce an anti-tumour immune response, and immunotherapies rely on modulating the host immune system to induce an anti-tumour immune response. However, the immune response to such therapies is often reliant on the immunogenicity of a tumour. Tumour immunogenicity varies greatly between cancers of the same type in different individuals and between different types of cancer. So, what do we know about tumour immunogenicity and how might we therapeutically improve tumour immunogenicity? We asked four leading cancer immunologists around the world for their opinions on this important issue.

Original languageEnglish
Pages (from-to)307-313
Number of pages7
JournalNature Reviews Cancer
Volume12
Issue number4
DOIs
StatePublished - Apr 1 2012

Fingerprint

Neoplasms
Immunotherapy
Immune System
Radiotherapy
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Blankenstein, T., Coulie, P. G., Gilboa, E., & Jaffee, E. M. (2012). The determinants of tumour immunogenicity. Nature Reviews Cancer, 12(4), 307-313. https://doi.org/10.1038/nrc3246

The determinants of tumour immunogenicity. / Blankenstein, Thomas; Coulie, Pierre G.; Gilboa, Eli; Jaffee, Elizabeth M.

In: Nature Reviews Cancer, Vol. 12, No. 4, 01.04.2012, p. 307-313.

Research output: Contribution to journalArticle

Blankenstein, T, Coulie, PG, Gilboa, E & Jaffee, EM 2012, 'The determinants of tumour immunogenicity', Nature Reviews Cancer, vol. 12, no. 4, pp. 307-313. https://doi.org/10.1038/nrc3246
Blankenstein, Thomas ; Coulie, Pierre G. ; Gilboa, Eli ; Jaffee, Elizabeth M. / The determinants of tumour immunogenicity. In: Nature Reviews Cancer. 2012 ; Vol. 12, No. 4. pp. 307-313.
@article{03e8021ec8e7406d920352e40d48c0c1,
title = "The determinants of tumour immunogenicity",
abstract = "Many standard and targeted therapies, as well as radiotherapy, have been shown to induce an anti-tumour immune response, and immunotherapies rely on modulating the host immune system to induce an anti-tumour immune response. However, the immune response to such therapies is often reliant on the immunogenicity of a tumour. Tumour immunogenicity varies greatly between cancers of the same type in different individuals and between different types of cancer. So, what do we know about tumour immunogenicity and how might we therapeutically improve tumour immunogenicity? We asked four leading cancer immunologists around the world for their opinions on this important issue.",
author = "Thomas Blankenstein and Coulie, {Pierre G.} and Eli Gilboa and Jaffee, {Elizabeth M.}",
year = "2012",
month = "4",
day = "1",
doi = "10.1038/nrc3246",
language = "English",
volume = "12",
pages = "307--313",
journal = "Nature Reviews Cancer",
issn = "1474-175X",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - The determinants of tumour immunogenicity

AU - Blankenstein, Thomas

AU - Coulie, Pierre G.

AU - Gilboa, Eli

AU - Jaffee, Elizabeth M.

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Many standard and targeted therapies, as well as radiotherapy, have been shown to induce an anti-tumour immune response, and immunotherapies rely on modulating the host immune system to induce an anti-tumour immune response. However, the immune response to such therapies is often reliant on the immunogenicity of a tumour. Tumour immunogenicity varies greatly between cancers of the same type in different individuals and between different types of cancer. So, what do we know about tumour immunogenicity and how might we therapeutically improve tumour immunogenicity? We asked four leading cancer immunologists around the world for their opinions on this important issue.

AB - Many standard and targeted therapies, as well as radiotherapy, have been shown to induce an anti-tumour immune response, and immunotherapies rely on modulating the host immune system to induce an anti-tumour immune response. However, the immune response to such therapies is often reliant on the immunogenicity of a tumour. Tumour immunogenicity varies greatly between cancers of the same type in different individuals and between different types of cancer. So, what do we know about tumour immunogenicity and how might we therapeutically improve tumour immunogenicity? We asked four leading cancer immunologists around the world for their opinions on this important issue.

UR - http://www.scopus.com/inward/record.url?scp=84858797296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858797296&partnerID=8YFLogxK

U2 - 10.1038/nrc3246

DO - 10.1038/nrc3246

M3 - Article

C2 - 22378190

AN - SCOPUS:84858797296

VL - 12

SP - 307

EP - 313

JO - Nature Reviews Cancer

JF - Nature Reviews Cancer

SN - 1474-175X

IS - 4

ER -